CNS Pharmaceuticals, Inc. financial data

Symbol
CNSP on Nasdaq
Industry
Pharmaceutical Preparations
Location
2100 West Loop South, Suite 900, Houston, TX
State of incorporation
NV
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 55.2 % -66.3%
Debt-to-equity -235 % -272%
Return On Equity 696 %
Return On Assets -515 % -102%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57.5M shares +995%
Common Stock, Shares, Outstanding 33.4M shares +695%
Entity Public Float 8.78M USD 0%
Common Stock, Value, Issued 33.4K USD +695%
Weighted Average Number of Shares Outstanding, Basic 22.2M shares +26451%
Weighted Average Number of Shares Outstanding, Diluted 22.2M shares +26451%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12.1M USD -5.8%
General and Administrative Expense 5.02M USD -13.7%
Operating Income (Loss) -17.1M USD +8.27%
Nonoperating Income (Expense) 24.6K USD +230%
Net Income (Loss) Attributable to Parent -17.1M USD +8.36%
Earnings Per Share, Basic 96.2 USD/shares +99.5%
Earnings Per Share, Diluted 96.2 USD/shares +99.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.97M USD +667%
Assets, Current 7.39M USD +258%
Property, Plant and Equipment, Net 2.8K USD -19.3%
Assets 7.41M USD +218%
Accounts Payable, Current 3.57M USD +627%
Accrued Liabilities, Current 260K USD -5.94%
Liabilities, Current 4.06M USD -0.29%
Liabilities 4.06M USD -0.29%
Retained Earnings (Accumulated Deficit) -81.2M USD -26.6%
Stockholders' Equity Attributable to Parent 3.35M USD
Liabilities and Equity 7.41M USD +218%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.19M USD +33.8%
Net Cash Provided by (Used in) Financing Activities 3.46M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 300M shares +300%
Common Stock, Shares, Issued 33.4M shares +695%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.97M USD +667%
Interest Paid, Excluding Capitalized Interest, Operating Activities 6.63K USD +21.9%
Deferred Tax Assets, Valuation Allowance 12.8M USD +46.9%
Depreciation 818 USD -36%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 6.67M USD -22.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 84.6M USD +35.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 15K USD +51.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%